Novartis nomme Patrick Horber, Docteur en médecine, au poste de President, International, alors que Marie-France Tschudin, President, Innovative Medicines International et Chief Commercial Officer, quitte le Comité exécutif de Novartis
September 06, 2023 01:15 ET
|
Novartis Pharma AG
Après près de sept années chez Novartis et plus de quatre années en tant que membre du Comité exécutif de Novartis, Mme Tschudin poursuivra sa carrière de leader en dehors de Novartis Le Dr Horber...
Novartis ernennt Dr. Patrick Horber zum President, International, da Marie-France Tschudin, President, Innovative Medicines International und Chief Commercial Officer, aus der Geschäftsleitung von Novartis ausscheidet
September 06, 2023 01:15 ET
|
Novartis Pharma AG
Nach fast sieben Jahren bei Novartis und mehr als vier Jahren als Mitglied der Geschäftsleitung wird Marie-France Tschudin ihr nächstes Führungskapitel ausserhalb von Novartis beginnen Dr. Horber...
Novartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six years
August 28, 2023 08:15 ET
|
Novartis Pharma AG
Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six years...
Novartis completes acquisition of Chinook Therapeutics
August 11, 2023 11:30 ET
|
Novartis Pharma AG
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin A...
Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticaria
August 09, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across...
Novartis erzielt kräftige Umsatz- und Margensteigerungen und erhöht die Prognose. Aktienrückkaufprogramm von USD 15 Milliarden angekündigt; der Verwaltungsrat unterstützt den Spin-off von Sandoz¹˒²
July 18, 2023 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Umsatz wuchs im zweiten Quartal um +9% (kWk3, +7% USD), und das operative Kernergebnis verbesserte sich um +17% (kWk, +9% USD)Innovative Medicines (IM)...
Novartis réalise une forte croissance de son chiffre d’affaires et de sa marge, relève ses prévisions et annonce un rachat d’actions d’USD 15 milliards¹; le Conseil d’administration approuve le spin-off de Sandoz²
July 18, 2023 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 LRAu T2, hausse du chiffre d’affaires de +9% (tcc3, +7% USD) et du résultat opérationnel core de +17% (tcc, +9% USD)Innovative Medicines (IM): hausse du...
Novartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²
July 18, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core...
Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share)
June 12, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare,...
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
June 02, 2023 08:00 ET
|
Novartis Pharma AG
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of...